2023-11-23 07:00:12
The Novo Nordisk laboratory factory in Chartres, July 25, 2022. ARNAUD HEBERT / REA
A few kilometers from the city center of Chartres, the Novo Nordisk laboratory factory, established in the Eure-et-Loir conurbation for around sixty years, is preparing to experience a turning point. The Danish pharmaceutical company, champion of diabetes treatments, announced on Thursday, November 23, an investment of 2.1 billion euros on its French industrial site in order to expand the group’s global production capacities.
A great achievement for the French factory, including insulin injector vials and pens « made in Chartres » already flood nearly 85 countries around the world each year, and allow more than 8 million patients to regulate their diabetes daily. It was also an opportunity for the President of the Republic to celebrate on site a national victory on the front of industrial reconquest, one of his key themes.
With this major financing from Novo Nordisk, Emmanuel Macron intends to confirm the fruits of a “method” inaugurated in 2018 with Choose France, the annual high mass of foreign investment in France, and aimed at favoring face-to-face meetings. -strategic meetings with big bosses looking for a home base for their future investments. Chartes thus blew victory to Ireland, one of the other European countries competing against France.
The only European production site outside of Denmark
This investment reinforces the importance of the Chartres factory (around 1,600 employees), Novo Nordisk’s only European production site outside of Denmark. The pharmaceutical laboratory’s investment will double the current surface area of the site over the coming years to reach 230,000 m2, and is expected to create 500 new jobs. “High-tech equipment will offer the possibility of producing several different delivery devices”, details the company, which specifies that the first stages of construction have been launched. Delivery of the new buildings is expected to be completed between 2026 and 2028.
This expansion will allow Chartres to diversify its production, currently limited to products intended for the treatment of diabetes, to extend it to “the production of future therapeutic solutions in serious chronic diseases such as obesity”, including the Danish laboratory’s recent flagship drug, Wegovy. This treatment against obesity, the high-dose little brother of Ozempic, a drug against diabetes, has enjoyed dazzling success since its commercial launch in the United States in 2021.
You have 60% of this article left to read. The rest is reserved for subscribers.
#Novo #Nordisk #laboratory #invests #billion #euros #France